Rare disease focus Cycle Pharmaceuticals specializes in neurological, rare metabolic, and rare immunological conditions, many genetic, plus a treatment for rare leukemia, indicating a clear opportunity to position specialized therapies, companion services, and patient access programs to payers, providers, and patient groups.

US expansion Recent actions include launching CAVHANZA in the US, new commercial manufacturing agreement, and Detroit office presence, signaling readiness to scale market access, distribution, and payer engagement in the United States.

Strategic partnerships Acquisition of Applied Therapeutics and collaboration with Forma Life Sciences and Inceptua for free goods programs suggest avenues to co-develop or co-market rare-disease assets, expand patient support, and broaden distribution channels.

Oncology entry PHYRAGO, Cycle’s first US oncology product launched in 2025 with partner Handa Pharma, presents opportunities to cross-sell orphan oncology pipelines, engage specialty distributors, and pursue reimbursement strategies for niche cancer therapies.

Global access Expansion to Egypt and Morocco under the Free Goods Programme demonstrates a commitment to patient access in emerging markets, offering sales opportunities through regional partnerships, local regulatory navigation, and differentiated patient assistance offerings.